PubMed:33041111 / 988-1262
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T2 | 72-75 | Body_part | denotes | V-2 | http://purl.org/sig/ont/fma/fma13443|http://purl.org/sig/ont/fma/fma68615 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T6 | 64-68 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T10 | 152-153 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T7 | 69-71 | Chemical | denotes | Co | http://purl.obolibrary.org/obo/CHEBI_27638 |
| T8 | 109-119 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
| T9 | 191-210 | Chemical | denotes | lopinavir-ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
| T10 | 191-200 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T11 | 201-210 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T12 | 212-221 | Chemical | denotes | ribavirin | http://purl.obolibrary.org/obo/CHEBI_63580 |
| T13 | 226-236 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
| T14 | 237-241 | Chemical | denotes | beta | http://purl.obolibrary.org/obo/CHEBI_10545 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 28 | 64-75 | Species | denotes | SARS-Co-V-2 | Tax:2697049 |
| 29 | 109-119 | Chemical | denotes | remdesivir | MESH:C000606551 |
| 30 | 191-210 | Chemical | denotes | lopinavir-ritonavir | MESH:C558899 |
| 31 | 212-221 | Chemical | denotes | ribavirin | MESH:D012254 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T13 | 0-274 | Sentence | denotes | According to level 1 evidence reviewed here, the most effective SARS-Co-V-2 pharmacologic treatments include remdesivir for mild to severe disease, and a triple regimen therapy consisting of lopinavir-ritonavir, ribavirin and interferon beta-1b for mild to moderate disease. |